PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib
- This topic has 0 replies, 1 voice, and was last updated 2 years, 6 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement.
https://meetings.asco.org/abstracts-presentations/213153
Viewing 1 post (of 1 total)
- The forum ‘Chemotherapy & More’ is closed to new topics and replies.